| Revenue growth | Q2 +22.2%, H1 +22.0% YoY |
|---|---|
| Margins | Q2 EBITDA margin flat 21.7%; PAT margin 13.7% vs 14.5% |
| Demand visibility | IPM 8-9% CAGR FY25-30P; chronic share rising |
Growth
Q2 EBITDA ₹96.0Cr (+22.3%); H1 EBITDA ₹189.1Cr (+27.5%), margin 21.9% vs 20.9%.
Outlook
No numeric guidance given. Strategy: MR productivity, chronic expansion, in-licensing/M&A, regulated overseas markets.
Risks
Q2 PAT margin fell to 13.7% from 14.5% on higher D&A and brand acquisitions. H1 working capital outflow ₹48.6Cr.
Last quarter's promises, checked
Delivered
- FY27 rev growth 15% organic + ~2% inorganic (~17%) → H1 +22.0% (= BEAT)
- FY27 PAT growth 20% → H1 PAT +22.2% (= BEAT)
Partly delivered
- Margins within similar range (Q1 EBITDA 22%) → Q2 21.7%, H1 21.9%; PAT margin 14.2% → 13.7% (= PARTIAL)
Missed
- FY27 PAT growth 20% pace → Q2 PAT +15.3% (= MISS)
Investor Presentation filed with BSE, NSE: CORONA. Summary written with AI assistance from the document.
Corona Remedies Ltd: key numbers
- Share price
- ₹2,149.60
- Market cap
- ₹13,147 Cr
- Revenue (annual)
- ₹1,403 Cr
- Net profit (annual)
- ₹185.1 Cr
- P/E (TTM)
- 66.1×Sector 45.9×
- Promoter holding
- 69.00%+0.00% QoQ
- FII holding
- 4.21%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Corona Remedies Ltd
All →Corona Remedies Results Update
Corona Remedies released unaudited Q2 and H1 FY27 results highlights via press release. Revenue grew 22% year on year, with EBITDA and PAT also rising.
Corona Remedies Q2 FY27 Results: Net Profit ₹60.3 Cr, Up 15.3% YoY
Corona Remedies Ltd reported revenue from operations of ₹441.2 Cr (+22.2% YoY) and net profit of ₹60.3 Cr (+15.3% YoY) for Q2 FY27.
- Key figure
- Net profit ₹60.3 Cr · +15.3% YoY
Corona Remedies Business Update
Corona Remedies received GMP Compliance Certification from Brazil's ANVISA for its OSD and Hormone facilities in Ahmedabad. This validates export eligibility to the Brazilian pharmaceutical market.
Corona Remedies Board Meeting Date
Corona Remedies Limited will hold a board meeting on October 30, 2026. The board will consider unaudited financial results for the quarter and half-year ended September 30, 2026.
Corona Remedies Other Announcement
This filing contains quarterly shareholding pattern disclosures for Corona Remedies Ltd. It provides details on share distribution as required by regulatory compliance norms.
Corona Remedies Credit Rating
CARE Ratings has reaffirmed and upgraded the credit ratings assigned to Corona Remedies Limited's bank facilities, as disclosed in the latest regulatory filing.